Integra LifeSciences Holdings Corporation — Q2 2023 Form 10-Q Summary
Business context and reporting period
Integra develops and sells medical technologies in two reportable segments: Codman Specialty Surgical, focused on neurosurgery and surgical instruments, and Tissue Technologies, focused on wound reconstruction, surgical reconstruction, and nerve and tendon repair. The filing covers the three and six months ended June 30, 2023. Results are unaudited and are not necessarily indicative of full-year performance.
Key financial metrics
| Metric | Q2 2023 | Q2 2022 | Change |
|---|
| Revenue | $381.3 million | $397.8 million | Down 4.2% |
| Gross profit | $207.0 million | $249.4 million | Down 17.0% |
| Gross margin | 54.3% | 62.7% | Down 8.4 points |
| Operating income | $12.5 million | $59.9 million | Down 79.1% |
| Operating margin | 3.3% | 15.0% | Down 11.7 points |
| Net income | $4.2 million | $44.8 million | Down 90.7% |
| Diluted EPS | $0.05 | $0.54 | Down $0.49 |
| Metric | Six months 2023 | Six months 2022 | Change |
|---|
| Revenue | $762.1 million | $774.5 million | Down 1.6% |
| Operating income | $48.9 million | $106.0 million | Down 53.9% |
| Net income | $28.4 million | $77.7 million | Down 63.4% |
| Diluted EPS | $0.35 | $0.93 | Down $0.58 |
| Operating cash flow | $54.4 million | $110.8 million | Down 50.9% |
| Capital expenditures | $29.3 million | $18.7 million | Up $10.5 million |
Revenue and segment performance
- Codman Specialty Surgical revenue increased 5.1% in Q2 to $271.0 million and 2.8% for the six months to $519.2 million. Neurosurgery grew low single digits, while Instruments grew low double digits.
- Tissue Technologies revenue decreased 21.2% in Q2 to $110.2 million and 9.8% for the six months to $242.9 million, primarily due to the Boston-related product recall. Private Label revenue declined to $19.1 million in Q2 from $35.1 million.
- Q2 revenue included a $12.9 million provision for product returns related to the voluntary recall of Primatrix, Surgimend, Revize, and TissueMend. The company also recorded a $24.1 million inventory write-off.
- The company cited unfavorable foreign exchange impacts of $1.7 million in Q2 and $8.7 million for the six months. The divestiture of the traditional wound care business reduced revenue, while the SIA acquisition contributed $2.4 million in Q2 and $4.2 million for the six months.
Liquidity, debt, and capital allocation
- Cash and cash equivalents were $309.2 million at June 30, 2023, down from $456.7 million at December 31, 2022. Working capital was $673.8 million, compared with $840.6 million at year-end.
- Six-month cash flow used in financing was $173.4 million, including $150.0 million for the 2023 accelerated share repurchase, $29.1 million of debt repayments, and $7.6 million of debt issuance costs.
- Senior Credit Facility borrowings totaled $775.0 million, with a weighted-average interest rate of 6.6%. The facility was amended to mature on March 24, 2028 and converted from LIBOR to SOFR-based pricing. No revolving borrowings were outstanding.
- Securitization Facility borrowings were $90.8 million at a 6.3% weighted-average rate and mature on May 28, 2024.
- The carrying amount of the 0.5% convertible senior notes due August 2025 was $568.8 million. None of the stated conversion conditions existed at June 30, 2023.
- The company was in compliance with its debt covenants and stated that cash and available borrowings should be sufficient to finance operations and capital expenditures for the foreseeable future.
- On July 18, 2023, the board authorized a new $225 million share repurchase program, replacing the prior program; $75 million remained available under the prior authorization when replaced.
Material changes, outlook, and risks
- Boston facility: Following FDA inspections and a July 2023 warning letter concerning quality-system issues, the company initiated a voluntary recall of products manufactured at the Boston facility between March 1, 2018 and May 22, 2023 and temporarily halted manufacturing. Management expected manufacturing to resume by late Q4 2023, subject to remediation and FDA-related developments.
- Boston recall-related special charges totaled $28.1 million for the six months, including inventory write-offs and idle-capacity charges. The company recorded total special charges of $70.1 million for the six months, including acquisition and integration, structural optimization, EU medical-device regulation, and Boston recall items.
- The company anticipated resuming shipments of the CereLink intracranial pressure monitor in late Q3 2023 after a voluntary global product removal initiated in 2022.
- On July 24, 2023, a tornado damaged inventory at a storage facility near Le Locle, Switzerland. The company estimated the inventory write-off would not exceed $8 million and expected insurance recovery, but stated that the amount and timing of recovery were uncertain.
- Management continued to emphasize product innovation, international growth, expansion of care pathways, operational excellence, and integration of the SIA acquisition. Enrollment in the DuraSorb U.S. breast-reconstruction study was completed in June 2023.
- Key ongoing risks include regulatory and quality-system remediation, product recalls and liability exposure, supply-chain and manufacturing interruptions, foreign exchange, variable interest rates, leverage and refinancing, contingent acquisition payments, litigation, tax-law changes, and execution of restructuring and integration programs.
Most important facts for investors to verify
- Progress, costs, inventory availability, and FDA status related to the Boston facility recall and manufacturing restart.
- Timing and commercial impact of the CereLink product relaunch.
- Whether Tissue Technologies revenue and margins recover after the recall and whether Codman growth continues.
- Cash generation, inventory levels, liquidity, and compliance with leverage covenants as debt maturities approach, particularly the $90.8 million securitization facility due in May 2024 and the convertible notes due in August 2025.
- Actual insurance recovery and financial impact from the Le Locle tornado.
- Potential payments of up to $90 million under SIA contingent consideration arrangements and other acquisition-related obligations.
- Realization of management’s expected cost savings and the timing and magnitude of recurring special charges.
